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Anticoagulation is an effective treatment for aortic
mural thrombi
Michael E. Bowdish, MD,a Fred A. Weaver, MD,a Howard A. Liebman, MD,b Vincent L. Rowe, MD,a
and Douglas B. Hood, MD,a Los Angeles, Calif
Background: Aortic mural thrombi (AMT) in the absence of aortic disease are rare. The appropriate indications and the
efficacy of surgical thrombectomy, thrombolysis, and systemic anticoagulation remain controversial.
Methods: This study, set in an academic medical center, was a retrospective review of five patients with AMT in the absence
of aortic disease who underwent treatment between 1997 and 2001. The main outcome measures were morbidity,
mortality, and treatment outcome.
Results: Three patients were women, and ages ranged from 40 to 77 years. On admission, all patients had symptoms
related to thrombus embolization (extremity pain or abdominal pain). Two patients had a history of venous thrombo-
embolism (pulmonary embolism or deep venous thrombosis). Four patients had biochemical evidence of hypercoagu-
ability, and the fifth had malignant disease. Coagulation disorders included increased homocysteine (n  2) and factor
VIII (n  1), antithrombin III (n  1) and protein C deficiency (n  1), and familial dysfibrinogenemia (n  1). AMT
were located in the infrarenal (n  1), suprarenal (n  3), and descending thoracic (n  1) aorta. One patient needed
exploratory laparotomy and one needed lower extremity vascular procedures for visceral and limb-threatening ischemia,
respectively. Treatment with systemic anticoagulation therapy resulted in complete resolution on follow-up computed
tomographic scan or angiogram of the AMT at a median of 60 days.
Conclusion: Most patients in whom AMT develops in the absence of underlying aortic disease have underlying coagulation
disorders. Anticoagulation therapy alone allows resolution of AMT, with surgical intervention reserved for management
of end organ ischemia from thrombus embolization. (J Vasc Surg 2002;36:713-9.)
Atheromatous disease and cardiac sources are the most
common origins of arterial emboli and account for approx-
imately 85% of limb, visceral, or cerebral thromboembolic
events.1 The etiology of the remaining 15% of thromboem-
boli, termed “cryptogenic,” is an enigma.2 The recognition
that some of these cryptogenic emboli are caused by unex-
pected aortic mural thrombi (AMI) has increased as the
capability to image the aorta with computed tomography,
transesophageal echocardiography, or magnetic resonance
imaging has improved.3 Mural thrombi that develop in a
normal aorta have been described in the literature as spon-
taneous aortic thrombus, nonocclusive aortic thrombus, or
primary aortic thrombus. We prefer the term AMT, which
connotates aortic thrombi that develop in the absence of
preexisting aortic disease.
Although AMT may be an incidental finding, they are
usually first discovered during an evaluation for distal em-
boli to the viscera or extremities.4,5 In a study by Machleder
et al6 of 10,671 consecutive autopsies, the incidence rate of
AMT was 0.45% (48 cases), of which 17% (eight cases) had
autopsy evidence of distal embolization and 6% (three
cases) had major thromboembolic occlusions considered to
be related to the cause of death. In another series, Gagliardi
et al,7 found AMT to be responsible for 3.8% of all nonan-
eurysmal aortoiliac lesions operated on during a 9-year
period and for 5% of peripheral arterial emboli.
A review of the medical literature since 1981 yielded 78
reported cases of AMT in which a variety of treatments and
outcomes are described. Given the rare clinical recognition
of this lesion, the etiology and the optimal treatment re-
main a question. Proposed causes of AMT include under-
lying malignant disease, hematologic disorders, exogenous
steroid and estrogen use, and primary endothelial disor-
ders.8 Treatment options used have included aortic throm-
bectomy, thrombolytic therapy, and systemic anticoagula-
tion therapy alone, all with varying degrees of success.2-4,9,10
In this report, we review our experience with this rare
and incompletely understood entity, focusing on the effi-
cacy of systemic anticoagulation therapy as a primary treat-
ment and the underlying pathogenesis contributing to
AMT. Included are a comprehensive review of the medical
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literature contrasting the available literature with our own
institutional experience and a discussion of possible mech-
anisms by which anticoagulation therapy may promote lysis
of thrombus.
METHODS
Patients at the University of Southern California affili-
ated hospitals (University of Southern California University
Hospital, Norris Comprehensive Cancer Center, and Los
Angeles CountyUniversity of Southern California Med-
ical Center) between 1997 and 2001 with AMT were
identified with a query of the University of Southern Cali-
fornia Vascular Registry. Patients with aortic thrombus or
thrombosis in association with underlying aortic disease (ie,
atherosclerotic disease or an underlying aortic aneurysm) or
those with evidence of thrombus originating from other
sources (ie, intracardiac thrombus) were excluded.
The medical records of the identified patients were
reviewed for initial signs and symptoms, diagnostic studies,
treatment used, complications, biochemical characteriza-
tion of hematologic disorders, and ultimate outcomes.
Main outcome measures were morbidity, mortality, and
treatment outcome. This study was approved by the Insti-
tutional Review Board of the University of Southern Cali-
fornia and Los Angeles County Medical Center (Institu-
tional Review Board #018040).
RESULTS
Five patients (two men, three women) with ages rang-
ing from 40 to 77 years (mean, 51  15 years) were
identified with AMT. Three were white, and two were
Hispanic. Medical histories included congenital extrophy
of the bladder, familial hypofibrinogenemia, ovarian can-
cer, anemia from a fibroid uterus, and tobacco use. Other
medical comorbidities included asthma, diabetes mellitus,
and gout. No patient had evidence of preexisting vascular
disease in remote vascular beds (ie, coronary, cerebrovas-
cular, or peripheral arterial) on the basis of history and
physical examination. No patient was undergoing antico-
agulant, estrogen, or steroid therapy at the time of admis-
sion; however, two patients had used steroids in the remote
past. No patient had a family history of hypercoaguability,
but two patients had prior events of deep venous thrombo-
sis (DVT) or pulmonary embolism. One patient had lower
extremity DVTs develop after prolonged bed rest for re-
constructive urologic surgery 4 and 15 years earlier. The
other patient had familial hypofibrinogenemia and had a
DVT and two pulmonary embolisms develop after receiv-
ing cryoprecipitate before hip replacement surgery 18
months earlier.
All patients were admitted with symptoms that sug-
gested thrombus embolization: three with lower extremity
pain, one with unilateral extremity involvement, two with
bilateral extremity involvement, and two with abdominal
pain. No patient had abdominal and lower extremity pain,
nor did any patient have evidence of cerebral or upper
extremity embolization.
Diagnostic evaluations to characterize the site of distal
embolization and to localize the source of the responsible
thrombus were conducted in all patients. The two patients
with abdominal pain underwent abdominal and pelvic
computed tomographic scan, which revealed thickened
loops of small bowel in one patient and a suprarenal AMT
in both (Fig 1). The patient with thickened loops of small
bowel and a suprarenal AMT also underwent confirmatory
angiography after an initial exploratory laparotomy (Fig 2).
Aortography and bilateral lower extremity angiography
were used in the three patients with lower extremity isch-
emia. Multiple infrapopliteal emboli were identified in all
cases, and one infrarenal and descending thoracic AMT was
found. The third patient had a suprarenal AMT at the aortic
hiatus shown with magnetic resonance angiography that
was not apparent with angiography or transesophageal
echocardiography.
Management of the distal embolic event was deter-
mined by the severity of the symptoms and the end organ at
risk. Of the two patients with abdominal pain, one had
peritoneal signs and presumed bowel ischemia. At laparot-
omy, a small bowel resection was performed for a segment
of necrotic small bowel. The remainder of the small bowel
was viable with visible arterial pulsations within the mesen-
tery, suggesting that the known suprarenal AMT did not
extend to the proximal superior mesenteric artery and that
superior mesenteric artery exploration was not indicated at
that time. The other patient had mild abdominal pain but
no obvious peritoneal findings and underwent nonopera-
tive management.
In the three patients with lower extremity ischemia, one
had both lower extremities acutely at risk from multiple
embolic occlusions of the infrapopliteal arterial tree. Cath-
eter-directed thrombolytic therapy with recombinant tissue
plasminogen activator (t-PA) was instituted and resulted in
partial lysis of thrombus in one lower extremity. Lysis was
unsuccessful in the other, necessitating a below-knee am-
Fig 1. Abdominal computed tomographic scan of 50-year-old
woman with abdominal pain shows nonoccluding filling defect in
proximal aorta and splenic infarction.
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putation as a result of the extensive distal infrapopliteal
emboli not amenable to either embolectomy or revascular-
ization. Ultimately, the other extremity needed a popliteal
to peroneal artery bypass for limb salvage. The other two
patients with lower extremity emboli underwent treatment
with anticoagulation alone with resolution of limb ischemia
and no further progression.
All patients underwent systemic anticoagulation ther-
apy with either infusion of unfractionated heparin (n  4)
or a therapeutic dose (1 mg/kg) of subcutaneous low–
molecular weight heparin (n  1). The patient with ab-
dominal pain and peritoneal signs who initially underwent a
small bowel resection had reembolization before the estab-
lishment of anticoagulation therapy, necessitating an emer-
gent reexploration and embolectomy of the superior mes-
enteric artery 10 days after initial presentation. Another
patient had a large mobile AMT in the descending thoracic
aorta that was treated initially with therapeutic low–mo-
lecular weight heparin. Because of concerns of additional
thrombus embolization, the patient underwent an aortic
thrombectomy. No thrombus was found intraluminally,
and subsequent angiography after the aortotomy did not
reveal new emboli. The four patients who underwent treat-
ment with unfractionated heparin received 10 to 21 days of
intravenous therapy (goal activated partial thromboplastin
time, two to three times control) before full conversion to
long-term warfarin therapy (international normalized ratio
[INR], 2.5 to 3.5) with 2 to 3 days of overlap therapy. The
fifth patient was treated with initial and long-term thera-
peutic enoxaparin (antifactor Xa level, 0.3 to 0.8 units).
In all five patients, no additional episodes of emboliza-
tion from the AMT occurred once anticoagulation therapy
was established. No bleeding complications occurred, and
no patient died as a result of the AMT, its treatment, or
complications of thromboembolism. Follow-up computed
tomographic scan (n 2) or angiography (n 3) obtained
between 3 and 90 days (median, 60 days) after initiation of
anticoagulation therapy showed complete resolution of the
Fig 2. Abdominal aortogram (A, anteroposterior; B, lateral) obtained in same patient as in Fig 1 shows large filling
defect (arrow) in suprarenal aorta from 11th thoracic vertebra to celiac axis consistent with AMT. Note absence of
thrombus in visceral vessels as shown on lateral aortogram.
Fig 3. Follow-up abdominal computed tomographic scan shows
complete resolution of AMT after 3 months of anticoagulation
therapy in same patient as in Figs 1 and 2.
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AMT (Fig 3). No patient has had recurrent AMT or em-
bolic events at a mean follow-up period of 29 11 months
(median, 16 months).
In those patients without underlying malignant disease,
the following hematologic evaluation was conducted: his-
tory to elicit any previous thromboembolic events; consul-
tation by a hematologist experienced in coagulation abnor-
malities; and a biochemical screening assessment consisting
of activated protein C, antithrombin III, protein C, protein
S, factor V Leiden, lupus anticoagulant, homocysteine, and
antinuclear and anticardiolipin antibodies. If these bio-
chemical study results were normal, then further studies
were conducted, including factor 2, 7, and 8 activity levels
and fibrinogen and plasminogen levels.
Underlying coagulation defects were documented in all
patients and included elevation of homocysteine in one,
multiple coagulation abnormalities in two (elevated factor
VIII and increased homocysteine and deficiency of anti-
thrombin III and protein C), and familial dysfibrinogen-
emia of the thrombotic phenotype in one (Table). The final
patient had underlying ovarian malignant disease.
The patient with familial dysfibrinogenemia had further
characterization of the specific defect and was found to have
a truncated  chain of fibrinogen that resulted from a
genetic mutation causing an aberrant stop codon at amino
acid 348. This defect, previously undescribed and subse-
quently labeled fibrinogen Keokuk, results in a 50% reduc-
tion in fibrinogen  chain production and a subsequent
1000-fold increase in resistance to lysis by t-PA.11
DISCUSSION
The isolated development of an AMI in an otherwise
normal aorta and its importance as a cause of distal embo-
lization was first described by Williams et al3 in 1981. They
reported a series of 20 patients with acute embolic occlu-
sion of extremity arteries from emboli from a proximal
AMT. All patients were treated with aortic thrombectomy,
and at operation, both the external and the internal appear-
ances of the aorta were reportedly normal.3 Later clinical
reports by Gagliardi et al7 and Reber et al9 and a large
autopsy series by Machleder et al6 also documented AMT
in aortas of normal size devoid of intimal disease. These
series clearly established that AMT can develop in other-
wise normal aortas and should be considered a potential
source of emboli when investigations of atheromatous and
cardiac sources are unrevealing.
Although the aggressive surgical or interventional man-
agement of limb-threatening or visceral-threatening isch-
emia resulting from AMT embolization is a given, the
optimal management of the AMT itself remains unsettled.
Surgical thrombectomy, thrombolytics, and systemic anti-
coagulation therapy have all been described as definitive
treatments. A review of the medical literature since 1981
provides 78 patients in 25 individual case reports or series2-
10,12-27 in which the location, associated distal emboli,
treatment, and outcome of AMT are described.
The distribution of AMT in these 78 patients shows
that most AMT (64%) are located in the abdominal aorta,
and 28% in the descending thoracic aorta and 8% in the
ascending aorta or aortic arch. A similar distribution is
described in our series where four AMT were located in the
infrarenal or suprarenal aorta, with one located in the
descending thoracic aorta. Ninety-nine embolic events as-
sociated with AMT occurred in the 78 patients. Lower
extremity embolization was the most common location
(60%), followed by mesenteric emboli (18%). Eighty per-
cent of the emboli to the lower extremities arose from an
AMT in the abdominal aorta, and 20% arose from the
descending thoracic aorta. Of the mesenteric emboli, 56%
originated from the abdominal aorta and 44% came from
the thoracic aorta. AMT also embolized to the renal arteries
(6%), upper extremities (6%), and cerebral (2%) and coro-
nary (1%) arteries. AMT that had not yet embolized were
discovered incidentally in 4% of patients.
The treatment rendered to address the AMT was clearly
delineated in 71 of the 78 patients. Surgical thrombectomy
of the AMT was performed initially in 44 patients (62%).
No mortality or recurrent emboli were reported after sur-
gical thrombectomy, with the exception of one patient in
whom severe heart failure developed after removal of an
ascending AMT. Of the 44 patients reported in the litera-
ture who underwent thrombectomy as primary treatment
for AMT, 41 of these patients had aortic thrombectomies at
the site of AMT (thoracic, suprarenal, or infrarenal aorta).
AMT and associated coagulation defects
Patient age (y)
and gender Location of AMT Coagulation defect Value*
45; male Descending thoracic Familial dysfibrinogenemia
Fibrinogen level 20 mg/dL (2)
44; male Suprarenal Homocysteine 14.1 mol/L (1)
50; female Suprarenal Antithrombin III 8.1% (2)
Protein C 38% (2)
45; female Suprarenal Ovarian malignant disease N/A
40; male Infrarenal Homocysteine 15.2 mol/L (1)
Factor VIII 218% (1)
*Normal values as follows: homocysteine; males, 4.0 to 12.0 mol/L; females, 4.0 to 10.0 mol/L; antithrombin III: 85% to 116% normal activity; protein
C: 75% to 158% normal activity; factor VIII: 57% to 137% normal activity; fibrinogen: 155 to 369 mg/dL.
N/A, Not applicable.
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In the series by Reber et al9 and Lau, Blanchard, and Hye,2
one patient each with infrarenal AMT underwent infrarenal
aortic resections and reconstruction with aortobifemoral
grafts, and one patient with a descending thoracic AMT
reported by Rubin et al14 underwent aortic resection with
prosthetic tube graft reconstruction. No patients under-
went remote thrombectomy of the AMT with femoral
artery access and balloon embolectomy.
Williams et al,3 Gagliardi et al,7 and Reber et al9 state
that aortic thrombectomy for AMT is the preferred treat-
ment because the risk of recurrent embolization is high
even in the setting of anticoagulation therapy. Reber et al9
specifically address the issue of anticoagulation therapy and
describe three episodes of recurrent embolization that oc-
curred “within hours” of catheter embolectomy of the
distal emboli despite “full” heparinization. In the studies of
Williams et al3 and Gagliardi et al,7 all patients underwent
surgical thrombectomy as the primary treatment. The use
of anticoagulation therapy or thrombolysis as an alternative
to surgical thrombectomy was not considered.
Catheter-directed thrombolytic therapy to treat AMT
has been reported in a single patient.10 Dougherty et al10
described a patient with limb ischemia in whom infusion of
urokinase directed at the AMT resulted in resolution of the
AMT but further embolization to the popliteal artery and
infrapopliteal arterial tree. Although anecdotal, the compli-
cation of distal embolization in the setting of catheter-
directed thrombolysis of atherosclerotic induced thrombo-
ses is well described and one of the limitations of
thrombolytic therapy.28 The reembolization in this one
patient and the shown benefit of anticoagulation therapy
alone in this and other series do not support the use of
catheter-directed thrombolysis for the treatment of AMT.
There are no reports of systemic thrombolysis being used
for primary treatment of AMT.
In this series, systemic anticoagulation therapy effec-
tively treated all AMT and prevented reembolization. The
effectiveness of anticoagulation therapy alone is evidenced
by the patient whose descending thoracic AMT had re-
solved before surgical thrombectomy. On the basis of this
experience, we have used anticoagulation therapy as the
initial treatment for the subsequent four patients we man-
aged with AMT. Complete thrombus resolution and pro-
tection from reembolization were observed, provided that
anticoagulation therapy was promptly established. It
should also be noted that catheter-directed thrombolysis of
distal emboli in combination with systemic anticoagulation
therapy may hasten the resolution of a large AMT. This was
the case in one patient where thrombus resolution was
documented 3 days after institution of catheter-directed
lysis and systemic heparin infusion. In the other four pa-
tients, resolution of the AMT was shown at 57  30 days
(range, 18 to 90 days).
In addition to these patients, the use of systemic anti-
coagulation therapy with unfractionated heparin as a pri-
mary treatment for AMT has been reported in 26 additional
patients. Anticoagulation therapy resulted in no further
embolic events in 23 of these patients, and new embolic
episodes occurred in two patients. There were no bleeding
complications associated with anticoagulant therapy. The
overall reembolization rate on the basis of this series and the
reported literature is 6.5%. If the patients reported by Reber
et al,9 who had reembolization before planned aortotomy
despite purported adequate anticoagulation therapy, are
included, the reembolization rate in the literature is 14.7%.
The importance of immediate and full anticoagulation is
underscored by these findings and consistent with the
observation of reembolization in one of our patients in
whom anticoagulation therapy was delayed.
The optimal length of time of heparin therapy and the
intensity of warfarin anticoagulation therapy appropriate
for the treatment of AMT is unknown because no reports in
the literature address these issues for either AMT or arterial
thrombotic events in general. On the basis of the venous
literature, continuation of heparin anticoagulation therapy
for a minimum of 5 days and as long as necessary to obtain
an adequate INR with warfarin would seem prudent.29,30
Recommendations regarding the intensity of warfarin anti-
coagulation therapy can be based on venous events (INR,
2.0 to 3.0) or use of mechanical valves (INR, 2.5 to 3.5).
Given the arterial location and the risk of embolization and
that the risk of bleeding does not increase significantly until
the INR is greater than 4.0, an INR of 2.5 to 3.5 would
seem most appropriate for AMT therapy. The therapeutic
levels achieved in patients with AMT are only available in a
single case report by Stollberger, Kopsa, and Finsterer25 in
which the PTT was kept between 80 and 100 seconds and
the INR between 3.0 and 4.0. In this series, our four
patients treated with heparin received 10 to 21 days of
intravenous therapy (goal activated PTT, 2 to 3 times
control) before full conversion to warfarin sodium (INR,
2.5 to 3.5) with 2 to 3 days of overlap therapy, and the fifth
patient was treated with therapeutic enoxaparin (antifactor
Xa level, 0.3 to 0.8 units). To summarize, on the basis of
this small experience and the available literature, we would
recommend that patients with AMT who are undergoing
treatment with anticoagulation therapy alone remain on
therapeutic levels of intravenous heparin or low–molecular
weight heparin for a minimum of 5 days until such time that
they have no further evidence of peripheral embolization
and, beyond that, until an adequate intensity of oral anti-
coagulation (INR, 2.5 to 3.5) has been established for 24
to 36 hours.
The time course of AMT resolution likewise remains
incompletely understood as there are no reports in which
serial imaging studies were obtained to follow the course of
AMT resolution with anticoagulant therapy. Of the 23
patients reported in the literature in whom anticoagulation
therapy resulted in no further embolization of the AMT,
complete resolution of the thrombus was documented in
15. The other eight reports make no mention of document-
ing thrombus resolution; this is implied as no further
embolic events occurred. The methods used to document
resolution included computed tomographic scan (n  5),
aortogram (n  3), transesophageal echocardiography
(n 3), magnetic resonance angiography (n 1), surgical
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exploration (n  1), autopsy (n  1), and an unreported
method (n  1). Sindhav, Comp, and Chandrasekaran23
and Hassan, Zehr, and Freeman5 both report the earliest
resolution at 14 days. Overall, the median time to docu-
mentation of thrombus resolution was 74  68 days
(range, 14 to 270 days; median, 60 days), with 80% being
documented within 3 months, 53% within 2 months, and
40% between 2 weeks and 1 month. This time course of
resolution must be viewed with the caveat of its retrospec-
tive nature and that the thrombi may have resolved sooner
than documented in many of these patients, given the lack
of serial imaging.
The resolution of thrombi with anticoagulant treat-
ment alone has been reported for lower extremity venous
thromboses and pulmonary emboli, but resolution of arte-
rial thrombi is less well recognized.31,32 The mechanism by
which unfractionated heparin promotes lysis of thrombus is
distinct from its interaction with antithrombin III. Fibrino-
lytic activity is known to be enhanced after thrombus
formation through the balance between t-PA and plasmin-
ogen activator inhibitory type 1 (PAI-1). PAI-1 normally
inhibits the activity of t-PA; however, PAI-1 is inactivated
through the protein C pathway, which is initiated by the
formation of thrombin, thus increasing fibrinolysis. Un-
fractionated heparin has been shown to accelerate the inac-
tivation of PAI-1, allowing the activity of endogenous t-PA
to predominate, thereby promoting fibrinolysis.33 This has
been most convincingly shown in the use of thrombolytics
in clinical trials, especially for acute myocardial infarction.
Patients receiving heparin plus t-PA have been shown to
have better outcomes, presumably from increased efficacy
of lysis, over those receiving t-PA alone.34 The interactions
with low–molecular weight heparins are not as well known
but likely act in a similar manner, with the low–molecular
weight heparins shifting the balance toward fibrinolysis.
In the prior reports concerning AMT, 32 patients
underwent an evaluation for an existing coagulation disor-
der. Before 1995, only 21% of patients underwent such an
evaluation, whereas since that time, 67% of patients have
reportedly been investigated. This reflects the increasing
awareness and recent identification of new hypercoaguable
conditions. Of the 32 patients, 20 had negative hemato-
logic evaluation results without a demonstrable cause of the
AMT,5,12,15,18,20-22,26 and 12 had hypercoaguable condi-
tions identified.4,8,9,13,16,17,23,24,35-37 Our own experience
would suggest that hypercoaguability is a prerequisite for
the development of AMT because either a hematologic
abnormality or neoplasm was identified in all five patients.
The circulating factor abnormalities or antibodies asso-
ciated with AMT are varied and includes antiphospholipid
antibodies,13,36,37 activated protein C deficiency,9 anticar-
diolipin antibodies,4 antithrombin III deficiency,35 and
protein C and S deficiencies.8 Our study adds to this list
elevated factor VIII and familial dysfibrinogenemia of the
thrombotic phenotype. These coagulation defects or other
potential protagonists of thrombosis, such as hyperhomo-
cystinemia, polycythemia rubra vera, and malignant neo-
plasms, should be searched for in patients with AMT. Even
if evaluation results for an underlying coagulation disorder
are negative, treatment of any patient with an AMT with
lifelong anticoagulation therapy to prevent future throm-
botic events appears prudent.
In conclusion, aortic thrombi do occur in the absence
of underlying aortic disease. When recognized, patients
with AMT should undergo evaluation for a predisposing
hypercoaguable state and treatment with lifelong anticoag-
ulation therapy. Providing that anticoagulation therapy is
aggressively initiated, anticoagulation alone appears to be
an effective therapy and is associated with high rates of
thrombus resolution and a low incidence rate of reemboli-
zation. In a patient population that may have significant
medical comorbidities, use of anticoagulation as the pri-
mary therapy appears reasonable. With this paradigm, sur-
gical or interventional therapy would then be reserved for
the initial embolic complications and the occasional patient
who despite adequate anticoagulation therapy shows per-
sistence of the AMT or reembolization.
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